UNSPSC 51131718: Anagrelide

This classification denotes an antiplatelet agent with the molecular formula C10H7Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9X45X0051, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3h)-one but generally known as anagrelide, which bears US NIH Compound Identifier 2182. Anagrelide most often comes in base and hydrochloride forms. European Medicines Agency schedules Anagrelide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05499MIG.

UNSPSC 51131718 Anagrelide is a Commodity code for a specific pharmaceutical product, but the single recent state and local opportunity tagged under it — Sourcewell RFP #061626 for law enforcement equipment — shows no connection to anagrelide procurement. The source documents a cooperative purchasing vehicle that Sourcewell, a State of Minnesota local government unit and service cooperative, is running on behalf of participating entities across Washington state (including Franklin, Grant, Grays Harbor, Chelan, and Yakima counties) and numerous other jurisdictions nationwide. The RFP solicits proposals to establish a contracting solution for law enforcement equipment available to thousands of governmental agencies, higher education institutions, K-12 school districts, nonprofit organizations, tribal governments, and other public entities. No set-aside designations, incumbent vendors, or specific award values are identified in the available documentation.

The code shows little relevant recent activity; the single opportunity represents a significant mismatch between the pharmaceutical scope of the UNSPSC code and the actual procurement being solicited. Sourcewell's RFP #061626 closed June 16, 2026, and was administered through the Sourcewell Procurement Portal with questions directed to Mari Vielma at rfp@sourcewell-mn.gov or 888-894-1930. The resulting contract(s) will be available for future utilization through participating addenda, allowing flexibility across participating entities. Firms evaluating pharmaceutical procurement opportunities should verify whether anagrelide solicitations are actually being tagged under this code or whether the mismatch reflects cataloging variance within particular jurisdictional procurement systems.